Literature DB >> 29149420

Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy.

Mohammad Abuqbeitah1, Mustafa Demir2, Lebriz Uslu-Beşli2, Nami Yeyin2, Kerim Sönmezoğlu2.   

Abstract

The main target of this work is to examine blood clearance and external exposure for 177Lu-DOTATATE compared with new emerging 177Lu-PSMA therapy. Blood clearance and radiation exposure of 31 patients treated with 5.5 ± 1.1 GBq 177Lu-DOTATATE were compared to those of 23 patients treated with 7.4 GBq 177Lu-PSMA. Dose rates were measured at several distances and time points up to 120 h after treatment. Blood samples were collected conjunctively after infusion. Caregiver's cumulative dose was measured by means of an OSL (optically stimulated luminescence) dosimeter for 4-5 days and medical staff's dose was also estimated using electronic personal dosimeters. Finger dose was determined via ring TLD (Thermoluminescence Dosimeter) for radiopharmacists and nurses. Dose rates due to 177Lu-DOTATATE at a distance of 1 m, 4 h and 6 h after infusion, were 3.0 ± 2.8 and 2 ± 1.9 µSv/(h GBq), respectively, while those due to 177Lu-PSMA were 3.1 ± 0.8 and 2.2 ± 0.9 µSv/(h GBq). Total effective dose of 17 caregivers was 100-200 µSv for 177Lu-DOTATATE therapy. Mean effective doses to nurses and radiopharmacists were 5 and 4 µSv per patient, respectively, while those for physicists and physicians were 2 µSv per patient. For 177Lu-DOTATATE, effective half-life in blood and early elimination phase were 0.31 ± 0.13 and 4.5 ± 1 h, while they were found as 0.4 ± 0.1 and 5 ± 1 h, respectively, for 177Lu-PSMA. The first micturition time following 177Lu-DOTATATE infusion was noted after 36 ± 14 min, while the second and third voiding times were after 74 ± 9 and 128 ± 41 min, respectively. It is concluded that blood clearance and radiation exposure for 177Lu-DOTATATE are very similar to those for 177Lu-PSMA, and both treatment modalities are reasonably reliable for outpatient treatment, since the mean dose rate [2.1 µSv/(h GBq)] decreased below the dose rate that allows release of the patient from the hospital (20 µSv/h) after 6 h at 1 m distance.

Entities:  

Keywords:  177Lu-DOTATATE; 177Lu-PSMA; Blood clearance; Dose rate; Radiation exposure

Mesh:

Substances:

Year:  2017        PMID: 29149420     DOI: 10.1007/s00411-017-0721-6

Source DB:  PubMed          Journal:  Radiat Environ Biophys        ISSN: 0301-634X            Impact factor:   1.925


  13 in total

1.  Radiation protection for accompanying person and radiation workers in PET/CT.

Authors:  Mustafa Demir; Bayram Demir; Haluk Sayman; Sait Sager; Asm Sabbir Ahmed; Ilhami Uslu
Journal:  Radiat Prot Dosimetry       Date:  2010-12-23       Impact factor: 0.972

Review 2.  Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate.

Authors:  W H Bakker; W A P Breeman; D J Kwekkeboom; L C De Jong; E P Krenning
Journal:  Q J Nucl Med Mol Imaging       Date:  2006-12       Impact factor: 2.346

Review 3.  Preclinical and clinical studies of peptide receptor radionuclide therapy.

Authors:  Stefan E Pool; Eric P Krenning; Gerben A Koning; Casper H J van Eijck; Jaap J M Teunissen; Boen Kam; Roelf Valkema; Dik J Kwekkeboom; Marion de Jong
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

4.  A technique for the absolute measurement of activity using a gamma camera and computer.

Authors:  J S Fleming
Journal:  Phys Med Biol       Date:  1979-01       Impact factor: 3.609

5.  Radiation exposure for 'caregivers' during high-dose outpatient radioiodine therapy.

Authors:  Christopher J Marriott; Colin E Webber; Karen Y Gulenchyn
Journal:  Radiat Prot Dosimetry       Date:  2006-07-06       Impact factor: 0.972

Review 6.  Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.

Authors:  Dik J Kwekkeboom; Boen L Kam; Martijn van Essen; Jaap J M Teunissen; Casper H J van Eijck; Roelf Valkema; Marion de Jong; Wouter W de Herder; Eric P Krenning
Journal:  Endocr Relat Cancer       Date:  2010-01-29       Impact factor: 5.678

Review 7.  Outpatient therapeutic nuclear oncology.

Authors:  J Harvey Turner
Journal:  Ann Nucl Med       Date:  2012-01-07       Impact factor: 2.668

8.  [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.

Authors:  D J Kwekkeboom; W H Bakker; P P Kooij; M W Konijnenberg; A Srinivasan; J L Erion; M A Schmidt; J L Bugaj; M de Jong; E P Krenning
Journal:  Eur J Nucl Med       Date:  2001-09

9.  Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.

Authors:  Levent Kabasakal; Mohammad AbuQbeitah; Aslan Aygün; Nami Yeyin; Meltem Ocak; Emre Demirci; Turkay Toklu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-31       Impact factor: 9.236

10.  [177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney.

Authors:  Christina Swärd; Peter Bernhardt; Håkan Ahlman; Bo Wängberg; Eva Forssell-Aronsson; Maria Larsson; Johanna Svensson; Rauni Rossi-Norrlund; Lars Kölby
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

View more
  2 in total

1.  Impact of external cooling with icepacks on 68Ga-PSMA uptake in salivary glands.

Authors:  Ludwike W M van Kalmthout; Marnix G E H Lam; Bart de Keizer; Gerard C Krijger; Tessa F T Ververs; Rememrt de Roos; Arthur J A T Braat
Journal:  EJNMMI Res       Date:  2018-07-03       Impact factor: 3.138

Review 2.  Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy.

Authors:  Ute Hennrich; Klaus Kopka
Journal:  Pharmaceuticals (Basel)       Date:  2019-07-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.